Weil Company Inc. bought a new stake in Pfizer Inc. (NYSE:PFE) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 6,328 shares of the biopharmaceutical company’s stock, valued at approximately $230,000.
Other large investors also recently added to or reduced their stakes in the company. W.G. Shaheen & Associates DBA Whitney & Co acquired a new stake in Pfizer in the first quarter valued at $132,000. Braun Bostich & Associates Inc. acquired a new stake in Pfizer in the first quarter valued at $139,000. Clearwater Capital Advisors LLC acquired a new stake in Pfizer in the first quarter valued at $156,000. Goodwin Daniel L acquired a new stake in Pfizer in the second quarter valued at $171,000. Finally, Bristol John W & Co. Inc. NY acquired a new stake in Pfizer in the first quarter valued at $186,000. Hedge funds and other institutional investors own 68.64% of the company’s stock.
A number of research firms have weighed in on PFE. Cantor Fitzgerald set a $45.00 price target on Pfizer and gave the company a “buy” rating in a research note on Tuesday, July 31st. Bank of America raised their price target on Pfizer from $42.00 to $43.00 and gave the company a “buy” rating in a research note on Wednesday, August 1st. JPMorgan Chase & Co. restated a “buy” rating and issued a $42.00 price target on shares of Pfizer in a research note on Thursday, August 23rd. Societe Generale set a $43.00 price target on Pfizer and gave the company a “hold” rating in a research note on Thursday, November 1st. Finally, BMO Capital Markets raised their price target on Pfizer from $42.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, August 1st. Two analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $42.67.
PFE opened at $43.14 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer Inc. has a one year low of $33.20 and a one year high of $45.81. The stock has a market cap of $256.81 billion, a PE ratio of 14.48, a PEG ratio of 2.15 and a beta of 0.88.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.03. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The business had revenue of $13.30 billion for the quarter, compared to analysts’ expectations of $13.53 billion. During the same quarter in the previous year, the firm earned $0.67 earnings per share. The business’s revenue was up 1.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer Inc. will post 3 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.15%. The ex-dividend date of this dividend is Thursday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 51.32%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Read More: Discover Your Risk Tolerance
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.